期刊文献+

卵黄囊瘤裸鼠移植瘤模型的建立及其生物学特性的研究 被引量:2

A study on nude mice models and biological characteristics of yolk sac tumor
原文传递
导出
摘要 目的采取手术标本,在裸鼠皮下连续传代建立人卵黄囊瘤裸鼠移植瘤模型。方法切取睾丸卵黄囊瘤患儿肿瘤组织植入裸小鼠腹股沟皮下,连续传代。观察卵黄囊瘤移植瘤各代生长潜伏期、生长曲线。电子显微镜观察肿瘤组织超微结构、病理形态情况。并通过免疫组织化学染色检测动物模型标本的甲胎蛋白(AFP)、胎盘碱性磷酸酶(PLAP)、细胞角蛋白(CKPan)表达。同时分析肿瘤细胞的染色体数目。结果15个月中连续在裸鼠皮下传7代,成瘤率逐渐升高:前三代的成瘤率分别为20%、40%、65%,此后接种成瘤率为100%,肿瘤生长潜伏期为32d。移植瘤生长曲线与Gompentz函数符合。移植瘤保留了原卵黄囊瘤的组织学特征。免疫组织化学示卵黄囊瘤的标志物AFP、PLAP、CK表达阳性,与对照组比较,差异有统计学意义(P〈0.01)。染色体数目分析结果显示染色体数目波动于34~86,可见染色体缺失断裂,不同于正常裸鼠和人染色体数目。结论该模型基本保留了原肿瘤的生物学特性,是卵黄囊瘤基础及临床研究的良好模型。 Objective To establish stable nude mice models from human Yolk Sac tumor (YST) for purpose of experimental research. Methods Fresh YST'S tumor specimen from 2-yr old child was sliced and inoculated hypodermically into the limbs of nude mice with constituted passage. The tumor growth curves of each generation were monitored. The ultra-structural and pathological changes were observed on by electronic and light microscopy. The immunohistochemical staining was applied to observe the expression of AFP, PLAP and CK on tumor tissues. The numbers of chromosome within tumor tissue were analyzed simultaneously. Results During 15-month period of study, 7 generations of tumor division were recorded. The oncogenic rate within that of the first 3 generations was 20%, 40% and 65%, respectively. After the 4th generation, the oncogenic rate was 100%. The average la tency period of tumor in mice was 32 days. The growth curve corresponded to the Gompentz function. The transplanted tumors retained the original histological tumor characteristics. The AFP, PLAP and CK expression were positive by immunocytochemistry staining. The numbers of chromosome of tumor varied between 34~86, with chromosome depletion and breakage, which were different from that of normal nude mice and human(P〈0. 01). Conclusions The nude mice models from human YST retained the basic biological characteristics of the primary tumor and it is suitable for the fundamental and clinical researches on YST.
出处 《中华小儿外科杂志》 CSCD 北大核心 2009年第3期176-179,共4页 Chinese Journal of Pediatric Surgery
基金 浙江省自然基金资助项目(编号:Y204463) 浙江省卫生厅重点项目(编号:2004ZD009)
关键词 卵黄囊瘤 疾病模型 动物 肿瘤移植 生物学 Yolk sac tumor Disease models, Animal Neoplasm transplantation Biology
  • 相关文献

参考文献8

  • 1Boyle P. Testicular cancer: the challenge for cancer control. Lancet Oncol, 2004,5 : 56-61.
  • 2孙昉宪.肿瘤模型的最新进展——“转移鼠”模型[J].国外医学(肿瘤学分册),1996,23(5):287-290. 被引量:5
  • 3Zynger DL, Dimov ND, Luan C, et al. Glypican 3 : a novel maker in testieular germ cell tumors. J Surg Pathol, 2006, 30: 1570- 1577.
  • 4Abelev GI,EI' gort DA, Eraizer TL. Independence of alpha-fetoprotein expression from production of adult rat serum proteins in hepatoma McA-RH7777. Biull Eksp Boil Med, 1981,92:333-335.
  • 5初培国.细胞角蛋白染色在肿瘤诊断中的应用[J].中华病理学杂志,2004,33(3):273-276. 被引量:39
  • 6Yoshida M, Koshiyama M, Konishi M, et al. Ovarian dysgerminoma showing high serum levels and positive immunostaining of placental alkaline phosphatase and neuron specific enolase associated with elevation of serum prolactin level. Eur J Obstet Gynecol Reprod Biol, 1998,81 : 123-128.
  • 7Koh PO,Kim MO. Ethanol exposure decreases cell proliferation and increases apoptosis in rat testes. J Vet Med Sci, 2006, 68: 1013-1017.
  • 8Nakamura H, Takeshima H, Makino K, et al. Evaluation of residual tissues after adjuvant therapy in germ cell tumors. Pediatr Neurosurg, 2007,43 : 82-91.

二级参考文献1

  • 1Chu PG,Weiss LM.Keratin expression in human tissues and neoplasms.Histopathology, 2002,40:403-439.

共引文献42

同被引文献26

  • 1Oosterhuis JW, Looijeoga LH. Testicular germ-cell tttmours in a broader perspective Nat Rev Cancer,2005,5(3) :210-222.
  • 2Walsh TJ, Grady RW, Porter MP, et al. Incidence of testicu- lar germ cell cancers in US. children: SEER program experience 1973 to 2000. Urology.2006.68(2),402-405.
  • 3Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activi- ty of SU11248, a novel tyrosine kinase inhibitor targeting vas- cular endothelial growth factor and platelet-derived growth fac- tor receptors: determination of a pharmacokinetic/pharmaco- dynamic relationship. Clin Cancer Res, 2003,9 (1) : 327-337.
  • 4Abrams TJ, Lee LB, Murray LJ, et al. SUl1248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther, 2003,2 (5) : 471-478.
  • 5O'Farrell AM, Abrams TJ, Yuen HA, et al. SUl1248 is a no- vel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood,2003,101(9) :3597-3605.
  • 6Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activi- ty of SU11248, a novel tyrosine kinase inhibitor targeting vas- cular endothelial growth factor and platelet-derived growth fac- tor receptors: determination of a pharmacokinetic/pharmaco- dynamic relationship. Chn Cancer Res,2003,9(1):327-337.
  • 7Kandil DH, Cooper K. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol, 2009,16(2) : 125-129.
  • 8Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in earlystage breast carcinoma. J Natl Cancer Inst, 1992, 84 (24): 1875-1887.
  • 9Devouassoux-Shisheboran M, Mauduit C, Tabone E, et al. Growth regulatory factors and signalling proteins in testicular germ cell tumours: APMIS, 2003,111 (1) : 212-224.
  • 10O'Farrell AM, Abrams TJ, Yuen HA, et al. SUl1248 is a no- vel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood, 2003,101 (9) : 3597-3605.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部